Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia With High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination With Peg-Alpha Interferon (PEG-Intron) and Sargramostin (GM-CSF).

Trial Profile

Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia With High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination With Peg-Alpha Interferon (PEG-Intron) and Sargramostin (GM-CSF).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Imatinib (Primary) ; Peginterferon alfa-2b; Sargramostim
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Results from this and other five studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top